Prompted by this progress and our unique scalable synthesis of EBC-46 (Fig. 1A) (22), a PKC modulator approved for veterinary medicine and human use for cancer (23), we initiated studies, as described herein, to determine whether EBC-46 precursors and derivatives (Fig. 1B), incorporating our previously described PKC binding features (pharmacophore requirements) (Fig. 2A) (24, 25), would be effective LRAs. This evidence concerns the gene PRRT2 and cancer.